March 28th 2023
Overall survival after 10 years appears to be comparable regardless of whether patients 65 years or older received irradiation following surgery for low-risk, hormone receptor–positive breast cancer.
Novel Combination Strategies in HER2+ Metastatic Breast Cancer With CNS Disease
Comprehensive review of novel combination treatment strategies being explored for patients with HER2+ breast cancer and brain metastases.
HER2+ mBC With CNS Disease: Sequencing Therapy After Progression on Tucatinib
Panelists reflect on sequencing therapy for HER2+ metastatic breast cancer following disease progression on the tucatinib, trastuzumab and capecitabine regimen.
New Study Findings Will Generate Better Contralateral Breast Cancer Treatment Discussions Between Providers and Patients, Says ExpertJanuary 2nd 2023
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
Carriers of CHEK2 Mutations Have a 2-Fold Increased Risk for Contralateral Breast Cancer, Says ExpertJanuary 1st 2023
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
HER2CLIMB: Role of Tucatinib in Treating HER2+ mBC With CNS Disease
A panel of expert oncologists highlight the use of the tucatinib, trastuzumab and capecitabine regimen that was investigated in the HER2CLIMB trial to manage patients with HER2+ breast cancer and brain metastases.
HER2+ Metastatic Breast Cancer: Role of Radiation Therapy in Managing CNS Disease
Expert perspectives on the respective role of radiation therapy to manage brain metastases in the setting of HER2+ breast cancer.
Many Unanswered Questions About Risks for Contralateral Breast Cancer Led to CARRIERS Study, Says ExpertDecember 30th 2022
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Factors in Selecting Therapy for HER2+ Metastatic Breast Cancer With CNS Disease
Shared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.
Patient Case 2: HER2+ Breast Cancer With CNS Metastases
Switching to a patient case of brain metastases in HER2+ breast cancer, panelists highlight available therapeutic strategies in this setting.
Treatment Approaches in HER2+ mBC with Brain MetastasesDecember 22nd 2022
The panel reviews the treatment approaches for HER2+ mBC with active brain metastases and the factors to consider during treatment decision-making.
Case Presentation: A 60-Year-Old Woman with HER2+ mBC with Brain MetastasesDecember 22nd 2022
Virginia Kaklamani, MD, presents the case of a 60-year-old patient with stage III HER2+ mBC with brain metastases.
Strategies to Identify and Delay Brain Metastases in HER2+ Breast Cancer
A brief review on how best to identify, delay, or avoid brain metastases in patients diagnosed with metastatic HER2+ breast cancer.
Patient Scenario 1: A Case of Stage II HR+ Breast CancerDecember 16th 2022
Centering discussion on a patient scenario of stage II HR+ breast cancer, expert panelists consider how they would approach workup and selection of therapy.
HER2+ Metastatic Breast Cancer: Factors in Selecting Optimal Therapy
Having outlined available treatment options for patients with HER2+ metastatic breast cancer, expert panelists share which factors help to select optimal therapy.
FDA Approves New Dosing Regimens, Indications for Capecitabine Across Multiple Cancer TypesDecember 15th 2022
The FDA’s approval of new indications and dosing regimens of capecitabine across several cancer types, including breast cancer and colon cancer, marks the first drug to receive an update under the agency’s Project Renewal program.
Third-Line Treatment Options for HER2+ mBC after Progression on Trastuzumab DeruxtecanDecember 15th 2022
Heather McArthur, MD, describes what treatment options she would consider in the third-line setting for HER2+ mBC.
Early Efficacy Observed With Trastuzumab Deruxtecan±Pertuzumab for HER2+ Metastatic Breast CancerDecember 10th 2022
Patients with HER2-positive metastatic breast cancer experienced promising preliminary safety and efficacy with trastuzumab deruxtecan alone and in combination with pertuzumab.
Sacituzumab Govitecan Yields Improved Survival Regardless of Trop-2 Levels for HR+/HER2– Breast CancerDecember 10th 2022
Improvements in survival were observed in patients with pretreated, endocrine-resistant hormone receptor–positive, HER2-negative metastatic breast cancer who were treated with sacituzumab govitecan vs physician’s choice.
OS and EFS Improved With Neoadjuvant Chemotherapy/Carboplatin for Locally Advanced TNBCDecember 10th 2022
Patients with operable, locally advanced triple-negative breast cancer experienced notable improvements in survival following treatment with neoadjuvant carboplatin plus sequential taxane-anthracycline neoadjuvant chemotherapy.
Long-Term Data Show Neoadjuvant Olaparib Combination Does Not Outperform Carboplatin/Paclitaxel for HER2– Early Breast CancerDecember 10th 2022
Long-term findings from the phase 2 GeparOLA trial indicate that olaparib plus paclitaxel and carboplatin did not result in further benefit vs paclitaxel, and carboplatin for patients with HER2-negative, homologous recombination–deficient early breast cancer.
Expert Discusses Breast Conservation Therapy’s Impact on Recurrence for Multiple Ipsilateral Breast CancerDecember 9th 2022
Patients with multiple ipsilateral breast cancer might benefit from having a preoperative MRI before proceeding with breast conservation therapy, according to Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota.
Improved Survival Benefit With the Use of Circulating Tumor Count Application in First-Line Metastatic Breast CancerDecember 9th 2022
Results from the phase 3 STIC CTC trial found an improved overall survival when circulating tumor cells were used as a guide in combination with chemotherapy or endocrine therapy in patients with hormone receptor–positive/HER2-negative breast cancer.
Treatment Armamentarium for HER2+ Metastatic Breast Cancer
Comprehensive insight to the treatment armamentarium for HER2+ metastatic breast cancer throughout several lines of therapy.
Patient Case 1: Patient With HER2+ Metastatic Breast Cancer and no CNS Disease
Expert panelists open their discussion on HER2+ breast cancer by reviewing a patient case of metastatic disease with no CNS involvement.
Adding Palbociclib to Fulvestrant Did Not Yield Better Efficacy in ER-positive/HER2-Negative Metastatic Breast CancerDecember 9th 2022
Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer did not derive further benefit when palbociclib was added to fulvestrant.
Elacestrant Bests Standard of Care in PFS in ER Positive/HER2-Negative Metastatic Breast CancerDecember 8th 2022
Patients with ER-positive/HER2-negative metastatic breast cancer had improved progression-free survival when treated with elacestrant compared with standard of endocrine therapy.